Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN-TIMI 36 randomized trial

Circulation: Cardiovascular Quality and Outcomes

Volumn 1, Issue 2, 2008, Pages 107-115

  Arnold, Suzanne V ^a   Morrow, David A ^b   Wang, Kaijun ^a   Lei, Yang ^a   Mahoney, Elizabeth M ^a   Scirica, Benjamin M ^b   Braunwald, Eugene ^b   Cohen, David J ^a  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angina; Quality of life; Ranolazine; Trials

Indexed keywords

ACETANILIDE DERIVATIVE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; RANOLAZINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ACETANILIDES; ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DYSPNEA; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 77953246197     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.798009     Document Type: Article

References (24)

1. Brown N, Melville M, Gray D, Young T, Munro J, Skene AM, Hampton JR. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart. 1999;81:352-358. (Pubitemid 29167123)
2. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascu-larisation compared with a normal population. Heart. 2002;87:140-145. (Pubitemid 34098376)
3. Kim J, Henderson RA, Pocock SJ, Clayton T, Sculpher MJ, Fox KA; RITA-3 Trial Investigators. Health-related quality of life after interven-tional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol. 2005;45:221-228. (Pubitemid 40094729)
4. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on the management of patients with chronic stable angina). Circulation. 2003;107:149-158. (Pubitemid 36070948)
5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-e304.
6. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-1382. (Pubitemid 38496341)
7. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311-316. (Pubitemid 40164531)
8. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA; Combination Assessment of Rano-lazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316. (Pubitemid 38101603)
9. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566-575. (Pubitemid 44093970)
10. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783. (Pubitemid 46658646)
11. Spertus JA, Dawson J, Masoudi FA, Krumholz HM, Reid KJ, Peterson ED, Rumsfeld JS; Cardiovascular Outcomes Research Consortium. Prevalence and predictors of angina pectoris one month after myocardial infarction. Am J Cardiol. 2006;98:282-288. (Pubitemid 44062431)
12. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006;151:1186.e1-e9.
13. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842. (Pubitemid 30643610)
14. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary heart disease. Am J Cardiol. 1994;74:1240-1244. (Pubitemid 24375015)
15. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Anginal Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333-341.
16. Rose GA, Blackburn H. Cardiovascular survey Methods. Geneva, World Health Organization, 1968.
17. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106:43-49. (Pubitemid 34747440)
18. Cleary PD, Epstein AM, Oster G, Morrissey GS, Stason WB, Debussey S, Plachetka J, Zimmerman M. Health-related quality of life among patients undergoing percutaneous transluminal coronary angioplasty. Med Care. 1991;29:939-950.
19. Jenkins CD, Stanton BA, Jono RT. Quantifying and predicting recovery after heart surgery. Psychosom Med. 1994;56:203-212. (Pubitemid 24161042)
20. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey (SF-12): construction of scales and preliminary tests of reliability and validity. Med Care. 1996;32:220-233. (Pubitemid 126433231)
21. The EuroQol group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199-208.
22. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721. (Pubitemid 8066534)
23. Johnson JA, Coons SJ, Ergo A, Szava-Kovats G. Valuation of the EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics. 1998;13:421-433. (Pubitemid 28140701)
24. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE; COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-687.